Your browser doesn't support javascript.
loading
Double-modified oncolytic adenovirus armed with a recombinant interferon-like gene enhanced abscopal effects against malignant glioma.
Jiang, Shan; Chai, Hui-Hui; Fang, Xian-Long; Xu, Hou-Shi; Li, Tian-Wen; Tang, Qi-Sheng; Gu, Jin-Fa; Zhang, Kang-Jian; Liu, Xin-Yuan; Shi, Zhi-Feng; Cao, Xue-Ping; Wu, Zan-Yi; Zhou, Liang-Fu.
Afiliación
  • Jiang S; National Center for Neurological Disorders, Shanghai, China.
  • Chai HH; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
  • Fang XL; Neurosurgical Institute, Fudan University, Shanghai, China.
  • Xu HS; Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China.
  • Li TW; National Center for Neurological Disorders, Shanghai, China.
  • Tang QS; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
  • Gu JF; Neurosurgical Institute, Fudan University, Shanghai, China.
  • Zhang KJ; Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China.
  • Liu XY; Academician Expert Workstation of Fengxian District, Shanghai Yuansong Biotechnology Limited Company, Shanghai, China.
  • Shi ZF; National Center for Neurological Disorders, Shanghai, China.
  • Cao XP; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
  • Wu ZY; Neurosurgical Institute, Fudan University, Shanghai, China.
  • Zhou LF; Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China.
Neurooncol Adv ; 5(1): vdad117, 2023.
Article en En | MEDLINE | ID: mdl-37841695
Background: The development of new therapies for malignant gliomas has been stagnant for decades. Through the promising outcomes in clinical trials of oncolytic virotherapy, there is now a glimmer of hope in addressing this situation. To further enhance the antitumor immune response of oncolytic viruses, we have equipped a modified oncolytic adenovirus (oAds) with a recombinant interferon-like gene (YSCH-01) and conducted a comprehensive evaluation of the safety and efficacy of this modification compared to existing treatments. Methods: To assess the safety of YSCH-01, we administered the oAds intracranially to Syrian hamsters, which are susceptible to adenovirus. The efficacy of YSCH-01 in targeting glioma was evaluated through in vitro and in vivo experiments utilizing various human glioma cell lines. Furthermore, we employed a patient-derived xenograft model of recurrent glioblastoma to test the effectiveness of YSCH-01 against temozolomide. Results: By modifying the E1A and adding survivin promoter, the oAds have demonstrated remarkable safety and an impressive ability to selectively target tumor cells. In animal models, YSCH-01 exhibited potent therapeutic efficacy, particularly in terms of its distant effects. Additionally, YSCH-01 remains effective in inhibiting the recurrent GBM patient-derived xenograft model. Conclusions: Our initial findings confirm that a double-modified oncolytic adenovirus armed with a recombinant interferon-like gene is both safe and effective in the treatment of malignant glioma. Furthermore, when utilized in combination with a targeted therapy gene strategy, these oAds exhibit a more profound effect in tumor therapy and an enhanced ability to inhibit tumor growth at remote sites.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Neurooncol Adv Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Neurooncol Adv Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido